Company
We are a clinical stage pharmaceutical company developing a novel, well-tolerated, oral treatment for cancer, and inflammatory lung diseases.
Our pipeline consists of our azeliragon product candidate, currently in clinical development for the treatment of pancreatic cancer, brain metastasis, breast cancer, and glioblastoma, and inflammatory lung diseases including severe pneumonia, asthma, and COPD. Azeliragon clinical development targets cancers and inflammatory lung diseases for which innovative and more effective treatments are greatly needed.
RAGE, (Receptor for Advanced Glycation End-Products) plays a significant role in the initiation and progression of several cancers, and inflammatory lung diseases including pneumonia, asthma, and COPD. Its involvement in multiple conditions highlights its potential as a therapeutic target.
Cantex’s drug azeliragon is a potent oral RAGE inhibitor, with extensive human clinical data confirming its exceptional safety. Azeliragon is an orally administered small molecule, taken once-daily, that inhibits RAGE by blocking interaction with proteins (ligands) that bind and activate it. Overactivation of RAGE by these ligands stimulates cancer and its progression and metastasis, increases the risk of respiratory and kidney failure in severe pneumonia, and triggers inflammation, airway reactivity, and excess mucus production in asthma and COPD.
Azeliragon was originally under development for Alzheimer’s disease by the company from which Cantex licensed azeliragon. Clinical safety data from these trials, involving over 2000 individuals dosed for periods up to 18 months, indicates that azeliragon is very well tolerated. There is substantial mechanistic and pre-clinical evidence suggesting azeliragon could have efficacy as a treatment of cancer and inflammatory lung diseases.